CDX-2, a new marker for adenocarcinoma of gastrointestinal origin.

CDX2-88 is a recently developed monoclonal antibody to the intestinal epithelia-specific nuclear transcription factor CDX2. CDX2 immunohistochemistry has recently been shown to be useful in establishing gastrointestinal origin in metastatic tumors and will likely become a useful addition to the standard panel of immunostains for carcinomas of unknown primary sites. This article reviews the previous studies of this new antibody.